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Abstract: Yeast-like fungi from the Candida genus are predominantly harmless commensals that
colonize human skin and mucosal surfaces, but under conditions of impaired host immune system
change into dangerous pathogens. The pathogenicity of these fungi is typically accompanied by
increased adhesion and formation of complex biofilms, making candidal infections challenging to treat.
Although a variety of antifungal drugs have been developed that preferably attack the fungal cell wall
and plasma membrane, these pathogens have acquired novel defense mechanisms that make them
resistant to standard treatment. This causes an increase in the incidence of candidiasis and enforces the
urgent need for an intensified search for new specifics that could be helpful, alone or synergistically
with traditional drugs, for controlling Candida pathogenicity. Currently, numerous reports have
indicated the effectiveness of plant metabolites as potent antifungal agents. These substances have
been shown to inhibit growth and to alter the virulence of different Candida species in both the
planktonic and hyphal form and during the biofilm formation. This review focuses on the most
recent findings that provide evidence of decreasing candidal pathogenicity by different substances
of plant origin, with a special emphasis on the mechanisms of their action. This is a particularly
important issue in the light of the currently increasing frequency of emerging Candida strains and
species resistant to standard antifungal treatment.
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1. Introduction
Humans have co-evolved with millions of fungal species [1] of which only several hundred can be
infectious, most severely affecting individuals with immature or defective immune system—neonates
and elderly, individuals with hematological malignancies, acquired immunodeficiency syndrome
or congenital immunodeficiencies, and patients after prolonged treatment with broad-spectrum
antibiotics. Paradoxically, the development of advanced medical therapies could predispose some
patients to fungal infections that affect individuals under cancer care, autoimmune disease treatments,
trauma and intensive care, organ and hematopoietic stem cell transplantations, and patients that have
been subjected to surgery and the use of parenteral nutrition, intravenous catheters or mechanical
ventilation [2–7].
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Commonly identified fungal pathogens in humans are Candida species—usually commensal
yeasts that constitute a part of physiological microbiota, mildly colonizing human skin, oral cavity,
vagina, and gut, but changing into the opportunistic pathogens under conditions of inefficient
host immunity [8]. The worldwide distribution, plasticity in adapting to new challenging niches,
and diversity of species and strains of Candida genus determine that these yeast-like fungi cause a
wide range of different types of infections in susceptible individuals [9–11]. These might be infections
with high morbidity but not life-threatening, such as painful and itchy mucocutaneous candidiases
including candidal vulvovaginitis and balanitis, oropharyngeal candidiasis, internal overgrowth in
the gastrointestinal tract, keratitis or skin and nail mycoses [12–16]. However, currently, a serious
medical problem still remains with severe invasive fungal diseases associated with candidemia and
deep-seated candidiases of internal organs, characterized by the frequent nosocomial origin and high
mortality rates reaching 30–45% of infected patients [17–23]. Of more than two hundred species of the
Candida genus, about twenty present important medical significance, with most prevalent C. albicans
that accounts for nearly half of the diagnosed superficial and systemic candidiases in humans [24,25].
In addition to C. albicans, the other main etiological agents of candidal infections include C. glabrata,
C. parapsilosis, C. tropicalis, C. krusei, C. dubliniensis, C. kefyr, C. guilliermondii, C. lusitaniae and the
currently globally emerging C. auris, that all should be paid particular attention to because of their
diverse virulence strategies and increased resistance to the antifungals used [20,26,27]. The distribution
of particular species among different groups of susceptible patients varies noticeably depending on the
geographical region and specific risk factors predisposing to candidal infection that include a variety
of conditions based on the weakening of the host immune defense and shifting the balance from the
harmless commensal fungus to the dangerous pathogen. The currently recorded steady increase in
the incidence of infections caused by non-albican Candida species is in particular noteworthy [28,29].
Among this group of Candida fungi, the most common cause of invasive candidiasis in 2006–2016 was
C. glabrata in North America, Asia-Pacific region and Europe, whereas it was C. parapsilosis in Latin
America; and the second in frequency was C. parapsilosis in Europe and North America and C. tropicalis
in Asia–Pacific region and Latin America [30].
2. Virulence Factors of Candida Species to Be Considered for the Development of New
Antifungal Strategies
The successful colonization and occasional invasion of the human host are achieved by Candida
species through their diversified virulence and survival strategies, suited to the conditions in the host
organism. Of the highest importance is a tremendous facility of C. albicans cells for morphological
transition from yeast-like round cells to elongated pseudohyphae and filamentous hyphae [31]. Each of
these forms is equipped with a set of suitable adhesins or other surface-located proteins, enabling the
further penetration, dissemination, and persistence of pathogens in host tissues [32]. The main
adhesins mediate the adherence of C. albicans cells to abiotic surfaces, other microorganisms, and host
cells belonging to the agglutinin-like sequence (Als) protein family of glycosylphosphatidylinositol
(GPI)-linked cell surface glycoproteins [33,34], encoded by eight ALS genes (ALS1–7 and ALS9).
Another important adhesin is Hwp1—a hypha-associated GPI-linked protein involved in the direct
attachment of fungal cells to host epithelial cells and in the formation of drug-resistant biofilms [35].
Moreover, other GPI-linked proteins such as Eap1, Iff4 and Ecm33 support C. albicans cells’ adhesion to
host tissues. A similar effect was also observed for some proteins that are non-covalently associated
with the cell wall such as putative β-glucanase Mp65 and β-1,3-glucanosyl transferase Phr1 as well as
for the integrin-like surface protein Int1 [36].
The adhesion also triggers the possible formation of biofilms—highly complex microbial structures,
firmly fixed within an extracellular matrix and tightly attached to various surfaces. The biofilm ensures
resistance to antimicrobial agents and host immune factors, not only due to a tight architecture of the
formed fungal cell community but also by the increased expression of drug efflux pumps and the
formation of biofilm matrix, composed by glucans, mannans, proteins and nucleic acids, providing the
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protection and metabolic plasticity [37,38]. The major components of the biofilm matrix, β-1,3-glucans,
are regulated by the zinc-responsive transcription factor Zap1 and glucoamylases (Gca1 and Gca2),
glucan transferases (Bgl2 and Phr1) and exoglucanase Xog1 [39,40].
Another virulence trait is related to secreted extracellular hydrolases, e.g., phospholipases that
degrade phospholipids of host cell membranes and facilitate tissue penetration by fungal cells.
These enzymes are encoded by genes PLB1-5, and their contribution to Candida pathogenicity was
documented e.g., by attenuation in virulence of mutant strains with selective elimination of a particular
PBL gene [41]. Phospholipases are also associated with antifungal resistance and biofilm production [42].
Similar effects of reduced virulence of mutant strains were also noted for the deletion of genes LIP1-10
encoding the members of the lipase family [43].
Furthermore, aspartyl protease isoenzymes (SAP1-10) can be used by fungus in the damage of
epithelial and mucosal barrier proteins such as collagen, keratin, and mucin. Additionally, they also
degrade immunoglobulins, complement, cytokines and antifungal peptides [44–47] and can activate
the production of mediators of inflammation—kinins—bypassing the host control and facilitating the
invader spreading in the host tissues [48].
3. Current Methods for Treatment and Management of Superficial and Invasive Candidiases
Despite the advances in the medical treatment of mycoses, specific therapies are limited by
similarities in the structure and biochemical processes of human and fungal cells. Therefore,
the most effective drugs are based on the differences in the composition of the plasma membrane
occurring between host’s and pathogen’s cells, as well as on the cell wall formed exclusively by yeasts.
Other antifungals block nucleic acids or protein synthesis. For the treatment of Candida infections,
four most popular classes of drugs are currently used, namely echinocandins, azoles, polyenes and
fluoropyrimidines (Figure 1) [49].
Figure 1. Currently used groups of antifungal drugs with an indication of their cellular targets and the
mechanisms of resistance developed by Candida spp.
The first class of the most effective anticandidal drugs—echinocandins—contains semisynthetic
cyclic lipopeptides derived from natural fungal echinocandins that alter the cell wall biosynthesis
by inhibition of β-1,3-glucan synthase. Their action resulted in the reduction of the fungal cell wall
strength [50], increased osmotic instability and increased susceptibility to cell lysis [51]. Echinocandins
include caspofungin, micafungin and anidulafungin [52] and exhibit high activity against C. albicans,
C. tropicalis, C. glabrata and C. krusei. However, C. parapsilosis is intrinsically less susceptible to these
drugs due to a naturally occurring alteration in the gene encoding FSK1 subunit of β-1,3-glucan
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synthase [53]. Resistance of a similar origin was also identified for some C. glabrata and C. krusei
strains [54] in which the mutations in FSK1 and FSK2 genes were observed [55]. For C. auris isolates
it was demonstrated that the prevalence of resistance was 3.8%, i.e., of a similar order as that for
C. glabrata [56]. Echinocandins are also effective in the prevention of fungal biofilm formation [57] and
less toxic to human cells, thus being frequently used for first-line therapy in the treatment of invasive
candidiasis [58].
The next group of antifungals comprises drugs causing the alteration of the membrane function
such as polyenes represented by nystatin, natamycin and amphotericin B (AMB). All of them are natural
components isolated from bacteria from the Streptomyces genus. AMB is produced by S. nodosus [59],
natamycin by S. natalensis, S. chattanoogensis, S. lydicus and S. gilvosporeus [60], and nystatin by
S. noursei [61]. These highly lipophilic macrolides are able to penetrate the phospholipid bilayer of the
plasma membrane, in which they bind to ergosterol and promote the formation of transmembrane
channels resulting in cellular ionic imbalance and leading to cell death [62]. Although all Candida species
are susceptible to polyenes, the treatment of candidiasis caused by C. krusei and C. glabrata requires a
maximal safe dose of drugs; however, the usage of polyenes is limited by their nephrotoxicity [58].
This adverse effect results from the affinity of polyenes to cholesterol located in the membrane
of host cells, affecting the permeability of the renal tubules [63,64]. The best-known drug from
this group—AMB—is also effective against Candida spp. biofilm [57] and is often used in a safer
liposome-encapsulated form; however, this form is also more expensive, making this drug medication
for second-line therapy [65]. Moreover, nystatin or natamycin are useful only for the treatment of
superficial infections [60,66].
Although rare, the resistance to polyenes was described for some Candida strains isolated from
infected patients, with fungal cells overcoming polyene action by reducing the amount of ergosterol in
the plasma membrane. This is implemented by some defects in the ERG3 and ERG6 genes encoding
enzymes of ergosterol biosynthesis, or its substitution by non-ergosterol cytoplasmic sterols and
lipids [65,67].
Azoles belong to the fungistatic drugs targeting the cell membrane that inhibit an enzyme essential
for ergosterol biosynthesis. These drugs act by binding and inhibition of the lanosterol-14α-demethylase,
a cytochrome P450 enzyme (the product of ERG11 gene) mediating a rate-limiting step in ergosterol
biosynthesis. This results in the formation of toxic sterols (14-α-methylsterols), placed loosely within
lipid bilayers and decreasing tightness and stability of fungal cell membrane [59]. This group
of synthetic fungistatic drugs includes imidazoles (clotrimazole, econazole, miconazole and
ketoconazole), used primarily for the treatment of superficial infections, and triazoles (fluconazole,
itraconazole, voriconazole, posaconazole, isavuconazole) preferred for fighting against invasive
candidiasis [65,66,68]. Although generally well-tolerated, azoles also have several limitations, such as
hepatoxicity, mainly observed for clotrimazole and miconazole [69]. Moreover, there are problems
with azole efficiency. They are not active against Candida spp. biofilm [57]; C. krusei possesses an
intrinsic resistance to azoles and C. glabrata is less susceptible to them [66]. Additionally, the emerging
resistance to this group of drugs among isolates of Candida spp., especially C. auris, C. parapsilosis
and C. tropicalis is currently observed [54,70] as a consequence of the massive preventive application
of fluconazole [71,72] and common use of agricultural fungicides, structurally similar to azoles [73].
The resistance relies on the mutations or overexpression of ERG11 and ERG3 genes, which lead to
increased tolerance to methylated sterols and overexpression of drug-efflux pumps that transport
azoles outside of the fungal cell [65,67].
The last group of antifungals active against Candida spp. contains the factors that block
the synthesis of fungal nucleic acids and are represented by synthetic analogs of fluorinated
pyrimidine. The most commonly used is 5-fluorocytosine that enters the fungal cell via the transport
mechanism based on cytosine permease, and inside the fungal cell it is converted to 5-fluorouracil
that, after phosphorylation, can inhibit thymidylate synthase, essential during DNA replication.
After a further phosphorylation step, the compound formed is embedded in the RNA structure,
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causing premature chain termination [62,65]. The disadvantages of such treatment are the adverse side
effects of using 5-fluorocytosine, including the hepatic impairment, interference with bone marrow
function and rapid development of resistance by Candida species [68]. The resistance observed can
be due to a deficiency of enzymes involved in 5-fluorocytosine transport and metabolism [65,67]
or overproduction of natural substrate for thymidylate synthase [74]. Moreover, this type of drug
is not effective against C. krusei, which possesses an intrinsic resistance [66]. As a consequence,
5-fluorocytosine is applied for patients at low concentrations and in combination with other
antifungals [58], especially with AMB [68]. Currently, an important medical problem has been
generated due to the development of multidrug resistance by individual Candida strains and species,
as is the case of the emerging pathogen C. auris [75]. The Candida resistance to antifungals is associated
with the modulation of drug targets during the fungal morphological switch, the increase in the
abundance and activity of drug exporters, acquired resistance to environmental stress and biofilm
formation. The harmful side effects of currently used drugs, the increase in resistance to applied
treatments, and formation of the protective biofilm structure demonstrate an urgent need for directly
targeting and controlling different fungal virulence factors and selecting new types of drugs to limit
the resistance as an effective method of combating fungal infection.
4. A New Perspective for Plants’ Components in Antifungal Therapy
Recent reports indicate that plants are currently a promising source of substances with potent
fungicidal effects. Taking into consideration currently increasing drug resistance in Candida spp.,
intensive studies have been performed to discover new substances which may be helpful in candidiasis
prevention and in the eradication of fungal pathogens. Especially in the last five years, new achievements
in this field have demonstrated an interest in the anti-Candida activity of plant-derived crude extracts
or isolated phytochemicals. A unique feature of products extracted from plants is their high structural
diversity, which includes primary and secondary metabolites. A wide range of compounds isolated from
medicinal plants has been tested for the inhibition of Candida cell growth, adhesion, hypha formation,
and restriction of biofilm formation or destruction of mature biofilms. Primary anticandidal metabolites
are some peptides and lipids, while secondary metabolites with anticandidal activities include alkaloids,
terpenes, steroids, phenolic compounds (flavonoids, tannins and phenolic acids) and other organic
substances [76–82].
Although a great number of reports have demonstrated the antifungal effect of plant extracts
during candidiasis treatment, the mechanisms associated with their anticandidal activity are still
not satisfactorily understood. In this work, we summarize the current research focused not only
on the discovery of new plant components with antifungal potential but also on the mechanisms
responsible for their effect on the inhibition of growth and virulence of Candida spp. Therefore,
two distinct approaches are herein described. One concerns plant material-related mechanisms that
affect the cell wall, plasma membrane, and biofilm extracellular matrix of the most commonly isolated
Candida species, and the second, the action of plant extracts in the regulation of cellular functions,
including those related to fungal virulence.
4.1. Mechanisms of the Action of Plant Metabolites on the Fungal Cell Wall, Plasma Membrane and Biofilm
Extracellular Matrix
The cell wall and plasma membrane of Candida cells are the first targets for substances with
antifungal potential. Moreover, the extracellular matrix of fungal biofilms contributes significantly to
candidal virulence thus becoming a promising object for anticandidal treatment.
As the drug resistance in C. albicans is essentially multifactorial, and the production of biofilm
matrix is one of the relevant resistance-related mechanisms associated with the development of
biofilm, pharmacological interventions during the early phase of biofilm formation leading to the
reduction of its extracellular matrix are strongly correlated with increased treatment effectiveness [83].
Numerous reports have indicated that the mechanisms responsible for the reduction in carbohydrate
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content of biofilm extracellular matrix are associated with changed expression of gene encoding
enzymes modifying the amount of β-1,3-glucan (FKS1, BGL2P, PHR1P, XOG1), β-1,6-glucan (BIG1,
KRE5) and mannan (PMR1, ALG11, MNN9, MNN4-4, VRG4, VAN-1) [83,84].
In the last few years, several studies related to extracellular matrix destabilization by plant-derived
substances have been performed. Samel reports have shown reduced amounts of polysaccharides in the
extracellular matrix of Candida spp. biofilm after treatment with essential oils from Cinnamomum [85],
and ethanolic extracts from Aucklandia lappa [86] and Paeonia lactiflora [87]. Recently, a decreased
production of polysaccharides and extracellular DNA by fungal biofilm under the influence of
plant-derived substances—the alkaloid chelerythrine from Ranunculales and the terpene sanguinarine
from Zingiber zerumbet—was described [88]. Although these studies demonstrated a significant
decrease in the carbohydrate content within the fungal cell wall as a result of the action of plant-derived
substances, no specific mechanisms have been elucidated so far. An interesting report with terpene
cinnamaldehyde showed its fungicidal activity against C. glabrata isolates, demonstrating reduced
expression of the FKS1 gene responsible for β-1,3-glucan biosynthesis. However, in that study,
the content of extracellular carbohydrates was actually observed to increase [89]. On the other
hand, a different course of action for β-1,3-glucan reduction by poacic acid was reported in several
Candida spp. wild strains, as well as clinical isolates and mutant strains [90]. Poacic acid is a natural
plant metabolite with promising antifungal potential, found in the lignocellulosic hydrolysates of
grasses [91]. The sensibility of Candida spp. to poacic acid was shown to be regulated by the calcineurin
pathway and did not correlate with in vitro β-glucan synthase activity [90]. Furthermore, another study
demonstrated increased expression of IFD6 gene in Candida spp. caused by neopodin, an anthraquinone
from Rumex crispus [92]. IFD6 encodes an aryl alcohol dehydrogenase considered to be an inhibitor of
biofilm matrix production through quorum-sensing aryl and acyl alcohols [39]. This study opens up
new perspectives in the search for the mechanisms whereby the plant metabolites alter the cell wall
and biofilm composition.
Numerous cases of Candida resistance to antifungals regard the use of azoles responsible for
cellular membrane destabilization. It has been demonstrated that diverse plant components might
regulate ergosterol biosynthesis, including geraniol, a cyclic monoterpene alcohol present in diverse
plant-derived essential oils that showed a satisfactory antifungal activity [93]. This terpene was able
to inhibit the growth of Candida spp. at low MIC (Minimal Inhibitory Concentration) values. In that
study, a geraniol concentration-dependent reduction of ergosterol content in treated fungal cells was
observed, which was associated with the destruction of membrane integrity. In addition, an inhibitory
effect on the proton pump H+-ATPase in the plasma membrane was detected after geraniol treatment
and, as the conventional drugs—fluconazole and AMB—have no significant effects on H+-efflux,
a synergistic action of geraniol with these antifungals was suggested. Recently, another plant-derived
compound was reported to possess antifungal activity against non-albicans Candida species based
on similar mechanisms—β-citronellol which was able to decrease H+-efflux rates in C. glabrata
and C. tropicalis and to inhibit ergosterol biosynthesis [94]. Eucalyptal D, a formyl-phloroglucinol
meroterpenoid, isolated from Eucalyptus robusta, was also tested for antifungal properties in wild
strains as well as fluconazole-resistant clinical isolates of C. albicans [95]. This study showed that
fluconazole-susceptible strains were vulnerable to eucalyptal D, while fluconazole-resistant strains
also presented resistance against eucalyptal D; however, this compound might act synergistically
with fluconazole in the inhibition of the growth of resistant strains. Although eucalyptal D was able
to reduce fluconazole efflux in mutants strains, the up-regulation of the genes responsible for the
expression of ABC transporters CDR1 and CDR2 was observed, suggesting that this substance may
competitively inhibit fluconazole efflux due to its affinity to membrane transporters. On the other hand,
essential oils of Cinnamomum verum and Pelargonium graveolens rich in terpenes and phenylpropanoids
were able to act synergistically with fluconazole, resulting in membrane destabilization due to reduced
ergosterol biosynthesis and disturbed fatty acid homeostasis in C. albicans cells [96]. Gupta and
co-workers [89] also demonstrated the reduction of ergosterol synthesis in C. glabrata isolates by
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another terpene–cinnamaldehyde, due to a decreased expression of gene encoding enzymes involved
in ergosterol synthesis in the cell membrane (ERG2, ERG3, ERG4, ERG10, ERG11) and gene encoding
ABC transporters (CDR1).
Other plant-derived substances are also involved in membrane destabilization.
Patel et al. [97] reported the inhibition of ergosterol biosynthesis in an inhibitor-concentration
dependent manner, resulting in membrane disruption in cells treated with a flavonoid
(5,6,8-trihydroxy-7,4′-dimethoxyflavone) derived from Dodonaea viscosa var. angustifolia. Furthermore,
a Syzygium cumini methanolic extract exhibited antibiofilm activity against C. albicans without fungicidal
activity against planktonic cells [98]. The major component of the extract fraction with the largest
inhibitory properties against biofilm was quinic acid—a cyclic polyol. In that study, a synergistic
effect on inhibition of biofilm formation by this fraction combined with undecenoic acid was also
demonstrated. This effect correlated with a significant decrease in the polysaccharide and lipid content
within the extracellular biofilm matrix. The mixed substances were responsible for the down-regulation
of gene expression involved in ergosterol biosynthesis (ERG11) and in membrane transport (CDR1,
MDR1, and FLU1), the expression of which is mostly up-regulated in azole-resistant Candida spp. [68].
Therefore, the inhibition of efflux pumps was proposed as one of the mechanisms to counteract drug
resistance. In fact, it was demonstrated that the reduction of virulence of Candida spp. by quinic
acid and undecenoic acid might be attributed not only to decreased ergosterol levels but also to the
down-regulated expression of membrane transporters [98]. Berberine, a plant alkaloid identified
in several plants from the Berberis genus presented antiproliferative effect in fluconazole-resistant
C. tropicalis strains and improved its fungicidal activity [99]. Moreover, berberine was able to reinforce
fluconazole efficacy in these strains via different mechanisms, including ergosterol decrease and
efflux inhibition.
The effects of plant peptides on bacterial cell membrane perforation have been widely studied,
and it can be expected that these peptides may have similar activity against Candida spp. Earlier reviews
suggested that the number of plant-derived peptides with anticandidal activity was relatively
modest compared with other peptide sources [100–102]. Antimicrobial peptides from plants include
defensins, thionins, lipid transfer proteins, snakins, cyclotides, knottins and heveins [103]. They were
demonstrated to act via the membrane permeabilization, inhibition of cell wall synthesis, binding to
DNA or RNA, inhibition of DNA, RNA and protein synthesis, repression of protein folding and
metabolic turnover, as well as induction of apoptosis [100]. Nevertheless, the mechanisms involved
in their anticandidal action are still poorly understood. The last reports suggested membrane
permeabilization as the main mechanism of plant peptide action. Among these peptides, the most
studied have been defensins—short, cationic peptides with high cysteine content [104]. A defensin
from Heuchera sanguinea (HsAFP1) and recombined radish defensins (RsAFP1 and RsAFP2) presented
antifungal activity against planktonic C. albicans cells [105,106]. HsAFP1 showed a synergistic effect
with caspofungin on inhibition of C. albicans biofilm, while together with AMB strongly inhibited
the growth of the planktonic cells. It was also suggested that this defensin may also be involved in
the inhibition of yeast-to-hypha transition, but the mechanism of this process remained undefined.
Similar observations were described in another report, indicating a synergistic action of a smaller
linear HsAFP1-derived peptide (HsLin06_18) with several echinocandins (caspofungin, micafungin
and anidulafungin) against C. albicans [107]. These substances also significantly reduced in vitro
biofilm formation on catheters by C. glabrata and caspofungin-resistant C. albicans strains. It was
proposed that caspofungin facilitated HsLin06_18 internalization. Since plant defensins are in general
nontoxic towards mammalian cells, these achievements suggest an attractive perspective of a novel
candidiasis treatment. Furthermore, the plant-derived thionin from Capsicum annuum fruits (CaThi)
exhibited toxic effects against Candida spp. causing membrane permeabilization and facilitating the
entrance of fluconazole into the cell cytoplasm [108]. A protein from Oryza sativa, tetratricopeptide
domain-containing thioredoxin (OsTDX), also showed antifungal activity against Candida spp. via
a destabilizing and disrupting effect on fungal membranes [109]. Mechanisms that are related to
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facilitation of entry or a limitation of the efflux of antifungal drugs have also been elucidated for
plant-derived peptides [101]. A novel cysteine-rich peptide belonging to the heveins and isolated
from Pereskia bleo (bleogen pB1) was reported to be an anticandidal agent and its heparin-binding
property was indicated as essential for antifungal activity. However, this peptide was probably not
membrane-lytic and at high-salt conditions, its anticandidal activity was lost, suggesting the importance
of ionic interactions for bleogen pB1 antifungal action [110].
The above-described studies certainly allowthe affirmation that bioactive plant-derived substances
may act as anti-Candida agents due to alteration of the cell wall and membrane reorganization,
especially by decreasing polysaccharide and ergosterol synthesis, as well as by inhibiting drug efflux
and altering membrane permeability and hydrophobicity.
4.2. Mechanisms of Antivirulence Activity of Plant Metabolites on Candida Species
In the last five years, different plant-derived compounds have been studied for the regulation of
processes involved in fungal virulence-related mechanisms, such as adhesion, hypha formation or
production of extracellular proteases and other hydrolases. As described previously, Muthamil and
co-authors [98] demonstrated a synergistic effect of quinic acid with undecanoic acid against Candida
spp. isolates. In this report, the authors presented additional mechanisms for antifungal activity,
including the down-regulation of representatives of the ALS gene family (ALS1, ALS3) and decreased
expression of SAP1, SAP2, and SAP4 genes resulting in a remarkable reduction of extracellular aspartyl
protease activity in treated C. albicans. Furthermore, in that study, the genes HWP1, EGF1, CPH1, UME6,
EAP1, RAS1, HST7, and CST20, that are directly or indirectly involved in hyphal growth or filamentation,
were found to be appreciably down-regulated by quinic acid/undecanoic acid combination. In contrast,
increased expression of negative regulators of hyphal genes (NRG1, TUP1) was noticed. In a most
recent report, the effect of oleic acid against C. albicans and C. tropicalis was also explored through
transcriptomic and proteomic approaches [111]. This fatty acid presented good efficacy to inhibit
biofilm formation and decrease the virulence of Candida spp. through the regulation of protein activities
involved in glucose metabolism, ergosterol biosynthesis, lipase production, iron homeostasis and
amino acid biosynthesis. In addition, a significant change in the expression of genes that are related to
adhesion (ALS1, ALS3, EAP1), ergosterol biosynthesis (ERG11), SAP production (SAP1, SAP2, SAP4),
filamentation (HWP1, EFG1, CST 20, RAS1, UME6, HST7) and efflux pump activation (CDR1, MDR1)
was demonstrated. The antivirulence activity of teasaponin, a surfactant from tea seeds, was also
recently proposed [112]. Teasaponin showed moderate antifungal activity against the wild type,
efflux pump mutants and multidrug-resistant C. albicans strains. This metabolite inhibited hyphal
formation via the Ras–cAMP–PKA signaling pathways, leading to the significant down-regulation of
RAS1, ALS3, HWP1, CDC35, EFG1, ECE1 genes.
Plant-derived phenolic compounds have recently attracted increasing interest in their antifungal
activity. This large group includes numerous classes of compounds such as phenols, coumarins,
lignans, flavonoids, anthocyanins, tannins, quinones and stilbenoids. In fact, magnolol and honokiol,
two neolignan compounds isolated from Magnolia officinalis were able to inhibit adhesion, yeast-to-hypha
transition and biofilm formation in C. albicans via Ras1-cAMP-Efg1 pathway [113]. The treatment of
various C. albicans strains with these neolignans caused a significant decrease in the expression of genes
activated by this pathway and the MAPK cascade pathway (RAS1, EFG1, TEC1, CDC35, ECE1, HWP1,
ALS3) that play a key role in inducing adhesion of hyphal cells. Moreover, exogenous cAMP restored
the hyphal formation in magnolol- and honokiol-treated strains. Similar conclusions were reached
in another study, in which the alkaloid sanguinarine was shown to down-regulate some adhesion-
and hypha-specific/essential genes related to cAMP, such as ALS3, HWP1, ECE1, HGC1, and CYR1 in
various C. albicans strains [114]. Antibiofilm and antihyphal activities were also induced by camphor
and fenchyl alcohol, phenolic metabolites from Cedrus libani showing a down-regulation of gene
expression related to hyphal and biofilm formation (ECE1, ECE2, RBT1, EED1) [115]. These authors
also demonstrated that anthraquinone derivatives, such as alizarin (1,2-dihydroxyanthraquinone)
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and chrysazin (1,8-dihydroxyanthraquinone) could suppress C. albicans biofilm formation owing
to a decreased expression of several hypha-specific and biofilm-related genes (ALS3, ECE1, ECE2,
and RBT1) [116]. In other reports, it was demonstrated that shikonin, the major constituent of the
red pigment extracts from the roots of Lithospermum erythrorhizon exerted an inhibitory effect on
biofilm formation and mature biofilm destruction [117]. Several hypha- and adhesion-specific genes
were differentially expressed in shikonin-treated biofilm, including the down-regulation of ECE1,
HWP1, EFG1, CPH1, RAS1, ALS1, ALS3, CSH1 and up-regulation of TUP1, NRG1, BCR1. In turn,
phenylpropanoid cinnamaldehyde was able to decrease HWP1 gene expression leading to the enhanced
killing of C. albicans isolates and inhibition of biofilm formation [118]. Transcriptomic study on the action
of 6-gingerol and 6-shoagol on C. albicans cells showed that these polyphenolic compounds repressed
the expression of hypha/biofilm-related genes (ECE1 and HWP1), thus explaining the observed cell
growth primarily in planktonic form and a reduced adhesion [119]. The inhibition of Candida spp.
biofilm formation by nepodin, a phenolic compound that diminished the hypha- and biofilm-related
genes (ECE1, HGT10, HWP1, UME6) was also confirmed [92]. Furthermore, a flavonoid belonging
to the chalcone group—loureirin A, the major active component of Draconis sanguis, down-regulated
the expression of adhesion-related genes and hypha/biofilm-related genes (HWP1, IFF4, EAP1, ECE1,
RAS1, GPR1, CYR1, EFG1, CEK1, CPH1, UME6, PGA10) [120].
Other secondary metabolites from the terpene group also have been studied for their antifungal
activity. Coumarin, a natural plant terpene, strongly affected the capacity of C. albicans to form biofilm
and significantly impaired the preformed mature biofilm [121]. The expression of adhesion- and
hypha-related genes, including HWP1, HYR1, ECE1, and ALS3, was remarkably down-regulated by
coumarin. Moreover, the addition of exogenous cAMP partly returned the coumarin-induced inhibition
of hyphal development. Another compound of this group, zerumbone, a monocyclic sesquiterpene
extracted from Zingiber zerumbet significantly down-regulated the expression of biofilm-related and
hypha-specific genes (HWP1 and ALS3), causing the inhibition of biofilm formation and eradication of
preformed biofilm of C. albicans isolates [122].
In the last decade, new mechanisms for the regulation of Candida pathogenesis have been proposed.
The survival of Candida cells depends on their ability to adapt to adverse environmental conditions.
It has been shown that quorum-sensing molecules may play an important role in the regulation of
the fungal adaptation to environmental changes. For instance, regulation of apoptotic processes
in C. albicans cells by farnesol was demonstrated, suggesting that this quorum-sensing molecule is
involved in the regulation of the fungal cell life cycle with important implications for adaptation and
survival [123]. For this reason, new ideas have emerged to elucidate the mechanisms responsible for
the effectiveness of plant metabolites for the control of Candida pathogenesis. In fact, numerous studies
indicated the mediation of plant metabolites in pro-apoptotic processes, such as increased ROS release,
disruption of mitochondrial membrane potential, phosphatidylserine externalization, cytochrome C
release, metacaspase activation, DNA damage and nuclear fragmentation.
Cinnamaldehyde—a phenylpropanoid mentioned above for its anticandidal activity, also induces
pro-apoptotic processes. It was demonstrated that wild and isolated strains of C. albicans [124] and
C. glabrata [89] treated with cinnamaldehyde presented increased ROS production and increased
release of cytochrome C from mitochondria. Further effects observed in that study included an
enhanced calcium concentration in the cytoplasm and mitochondria, activation of metacaspase,
DNA damage, and chromatin condensation when membrane phosphatidylserine was exposed [124].
In another study, the effect of cinnamaldehyde, free or encapsulated in multimicellar liposomes,
on biofilm formation by C. albicans was examined [118]. In both cases, pro-apoptotic effects were
observed, leading to the inhibition of biofilm formation. However, these authors stated that the
unencapsulated metabolite, which showed lower efficacy, was involved in early and late apoptosis,
while the encapsulated compound induced early apoptosis and necrosis. Another phenylpropanoid,
associated with the induction of apoptosis in C. albicans cells, was hibicuslide C, extracted from
Abutilon theophrasti [125]. This compound exerted antifungal activity against C. albicans through the
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induction of early apoptosis followed by secondary necrosis. Hibisculide C induced an increase in ROS
production with the accumulation of hydroxyl radicals, which was accompanied by mitochondrial
dysfunction, metacaspase activation, and an increase in intracellular Ca2+ level. Furthermore,
flavonoids have been shown to be associated with apoptosis induction in Candida spp. Wang and
co-authors [126] reported that baicalin from Scutellaria might suppress the development of C. albicans
biofilms most likely due to inducing cell death via apoptosis. This flavonoid inhibited C. albicans biofilm
through extensive chromatin condensation, ROS accumulation, phosphatidylserine externalization,
nuclear fragmentation, metacaspase activation and cytochrome C release. In addition, the expression
of genes that are closely related to the Ras-cAMP-PKA pathway which has been considered responsible
for apoptosis regulation in C. albicans was up-regulated (RAS1, TPK1) or down-regulated (CAP1, PDE2).
Silibinin, the most active constituent of Silybum marianum extract, is also a flavonoid with anticandidal
activity exerted through the apoptotic mechanism [127].
For berberine, a herbal-derived alkaloid, antifungal activity tests against fluconazole-resistant
C. tropicalis isolates showed that this compound was involved not only in the modification of ergosterol
synthesis and efflux pump efficiency, but its antifungal properties were also related to apoptosis of
fungal cells, as documented by the berberine-induced ROS production [99]. Moreover, this effect was
more remarkable when cells were treated with berberine and fluconazole, indicating that the alkaloid
might be helpful in the treatment of fluconazole-resistant C. tropicalis strains. Another plant-derived
metabolite, lycopene, a carotenoid found in various fruits and vegetables was able to induce apoptotic
processes, employing antifungal activity during the early and late stages of apoptosis in C. albicans
cells [128].
The roles of proteins, peptides, and other primary metabolites in Candida pathogenicity attenuation
has also been reported. The role of the Kunitz type trypsin inhibitor from Cassia leiandra seeds (ClTI) in
the growth inhibition of Candida spp. was presented [129]. ClTI anticandidal activity was related not
only to the alteration of membrane permeabilization and H+-pump activity, but also to the induction of
oxidative stress and DNA damage, suggesting the involvement of apoptotic and necrotic mechanisms.
A similar mechanism was proposed for the antifungal activity of the thionin-like peptide (CaThi) from
Capsicum annuum fruits [108]. CaThi caused plasma membrane permeabilization in all yeasts tested but
induced oxidative stresses only in C. tropicalis. In addition, CaThi acted synergistically with fluconazole,
inhibiting all tested Candida spp., achieving even complete inhibition of C. parapsilosis growth.
Research on the anticandidal activity of lectins is also currently gaining an interest. A lectin
found in Punica granatum juice—PgTeL—has been found to be an antifungal agent against C. albicans
and C. krusei [130]. Candida treatment with PgTeL resulted in a decrease of intracellular ATP and
induced lipid peroxidation, suggesting a mechanism that involves oxidative stress, energetic collapse,
damage of the cell wall, and finally rupture of yeast cells.
In addition to the plant-derived products previously described, a number of further plant extracts
with antifungal activity have been reported (see Supplementary Table S1).
The studies outlined herein provided novel information on the antifungal activity of plants,
with emphasis on the mechanisms underlying the effects of plant metabolites on the inhibition of
the growth of Candida spp. and impairment of the candidal virulence. The discovery of these
mechanisms has opened up new perspectives for the treatment of candidiasis, especially in the problem
of eradication of drug-resistant strains. The mechanisms responsible for the resistance to antifungal
agents are continuously studied and it was established that drug resistance in Candida spp. is a complex
multifactorial phenomenon, involving molecular mechanisms often different for planktonic cells and
for biofilm. Therefore, the use of the traditional antifungal drug in combination with plant metabolites
can offer a new approach to candidiasis prevention and treatment. Such an approach might expand
the spectrum of antifungal activity and increase safety and tolerance due to the lower doses of applied
drugs. It should also be noted that in the majority of the reports describing the cytotoxicity of the plant
metabolites towards fungal cells, no adverse effects on mammalian cell viability have been shown.
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However, almost all related studies were performed in vitro; only in some cases, experiments have
been carried out on animal models, clearly meaning that these effects require further confirmation.
In conclusion, plants may be considered as a valuable source of bioactive substances that can help
in the fight with drug-resistant Candida strains and their exploration is highly recommended to offer
new effective antifungal therapies.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/21/17/
6131/s1. Supplementary Table S1. Antifungal activity of plant extracts on Candida spp.
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